Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 10, 2009

Cerenis Receives $3.2M to Support Development of HDL Products

Cerenis Receives $3.2M to Support Development of HDL Products

Cerenis receives $3.2 millino to develop CER-001

  • Cerenis Therapeutics has received a €2.5 million, or approximately $3.2 million, investment to finance its pipeline of HDL-related products for the treatment of cardiovascular and metabolic diseases.

    The financing will support continued development of the company's CER-001 program (recombinant HDL), which is currently in preclinical studies.

    The funds were granted by OSEO, a French public holding company that provides financial support to promising French companies.

    In 2008, the company initiated preclinical studies to enable an IND application for this product candidate. "This new source of funding will support our efforts to advance Cerenis HDL through the IND process and onto clinical development," says Jean-Louis Dasseux, Ph.D., president and CEO of Cerenis. "We are grateful to OSEO for its generous support of our efforts to bring this promising product candidate to market."ADNFCR-2184-ID-19019095-ADNFCR

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »